![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Subgroup Analyses From ONCEMRK: a Phase 3 Study of Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily in HIV-1-Infected Treatment-Naïve Adults at Week 96
|
|
|
Reported by Jules Levin
EACS - 16th European AIDS Conference, October 25-27, 2017. Milan
Di Perri G1; Cahn P2; Molina J-M3; Kaplan R4; Sax PE5; Squires K6; Rassool M7; Xu X8; Zhou Y8; Teppler H8; Hanna G8; Nguyen B-Y8; Greaves W8
for the ONCEMRK Study Group
1University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy; 2Fundación Huesped, Buenos Aires, Argentina; 3University of Paris 7 and Hôpital Saint-Louis, Paris, France; 4Desmond Tutu HIV Foundation, Cape Town, South Africa; 5Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA; 6Thomas Jefferson University, Philadelphia, PA, USA; 7University of Witwatersrand, Helen Joseph Hospital, Johannesburg, South Africa; 8Merck & Co., Inc., Kenilworth, NJ, USA
![1031171](../images/103117/103117-2/1031171.gif)
![1031172](../images/103117/103117-2/1031172.gif)
![1031173](../images/103117/103117-2/1031173.gif)
![1031174](../images/103117/103117-2/1031174.gif)
![1031174](../images/103117/103117-2/1031174.gif)
![1031175](../images/103117/103117-2/1031175.gif)
![1031176](../images/103117/103117-2/1031176.gif)
![1031177](../images/103117/103117-2/1031177.gif)
![1031178](../images/103117/103117-2/1031178.gif)
![1031179](../images/103117/103117-2/1031179.gif)
![10311710](../images/103117/103117-2/10311710.gif)
![10311711](../images/103117/103117-2/10311711.gif)
![10311712](../images/103117/103117-2/10311712.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|